Project to explore speed up of mRNA vaccine production deployable for local outbreaks
Share
- “AI-ready platform” could shorten current mRNA vaccine development timelines
- Platform designed to be easily deployable for local manufacture in outbreak response
- Continuous automated manufacturing would secure a rapid supply of vaccine
Oslo, Norway and Cambridge, UK, July 22, 2024 – Scientists who specialize in biocomputing are exploring a new, accelerated approach to developing and producing mRNA vaccine platforms that will use AI in a highly integrated continuous system to manufacture mRNA vaccines locally to contain or stop a disease outbreak.
The ambition is that taking a seamless automatic integration approach will help reduce the time it takes to develop and manufacture mRNA vaccine platforms, making them more easily and swiftly available for use in the event of a novel outbreak or a pandemic threat. The technology is suitable for transfer to LMIC regions to enable equitable access.
The $320 000 project, funded by VRƵ and led by BiologIC Technologies, could take one year to demonstrate a proof of concept. The scientists are using AI to identify the optimal operation of process modules to manufacture mRNA and LNPs. If this project succeeds the next step would be to develop a single integrated platform for manufacturing of mRNA-LNP. This can easily be deployed for decentralised scalable manufacturing at a local level as a rapid response to a pandemic.
Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations, said,
“Speed and decentralized vaccine manufacturing are key if we are to overcome the devastating vaccine inequity we witnessed during the COVID-19 pandemic. BiologIC Technologies’ innovative approach to vaccine manufacturing that could be rapidly deployed in case of an outbreak is a promising step towards a world where we are able to fight, contain and avert pandemics and fits well with VRƵ’s 100 Days Mission.”
Richard Vellacott, CEO of BiologIC Technologies, said,
“Our precision bioprocessing system, built by integrating and adapting common modules to execute end-to-end applications, is being rapidly adopted by modern biotechnology enterprises across many fields of advanced therapy development and manufacturing. The system, enabled by our proprietary biocomputer technology, is particularly amenable to accelerating the development of mRNA-LNP vaccines in response to a pandemic threat, rapid production of clinical trial materials and distribution of manufacturing to the point of need anywhere in the world. We are excited to collaborate with the eminent scientists at VRƵ to advance this leading bioprocessing capability and contribute towards protecting global populations from the threat of infectious diseases in an equitable way”.
VRƵ is funding this exploratory proof of concept project for the development of an automated and integrated system for the manufacture of mRNA vaccine and formulation into LNPs. BiologIC Technologies is developing an end-to-end, modular, continuous production system where each component of the mRNA-LNP production process will be developed and optimised in parallel. The plan is that completion of the project will interlink the modules to form a continuous process, demonstrating full automation to significantly accelerate vaccine development time and scalability. This would reduce vaccine manufacturing time compared to traditional manual processes.
- ENDS -
Notes to Editors
About VRƵ
VRƵ is an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. VRƵ has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to VRƵ’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.
About BiologIC Technologies
BiologIC’s mission is to empower scientists to build a better world using biology. Our precision bioprocessing platform helps make biology more “programmable” – that is, much easier to engineer and control. This lets our customers deliver faster R&D, process development and manufacturing of advanced biological products.
Proprietary biocomputer technology enables a new category of bioprocessing machine built using a modular, integrated architectures. Underpinned by granted patents and extensive knowhow, the machines are powerful yet simple and interactive to use, allowing the sophisticated manipulation of biology to make better, more consistent and more scalable products.
Right now, our high performance bioprocessing systems are trusted by leading biotech, biopharma and synbio organisations worldwide to create strategic value in applications including mRNA vaccines, cell and gene therapies, monoclonal antibodies, antibody-drug conjugates, viral vectors and stem cells.
Contact
VRƵ
[email protected]
+44 7387 055214
BiologIC Technologies
Richard Hatchett reflects on a “banner year for viruses” and looks ahead to 2025
Valneva expands access to Asia for its chikungunya vaccine with Serum
